Chiara A Wabl

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 6

Top Topics

Metastatic Breast Cancer

Top Venues

Future oncology (London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Bulent Cetin, Chiara A Wabl, Ozge Gumusay
Should one use the combination of abiraterone and poly(ADP-ribose) polymerase inhibitors as first-line therapy for all patients with metastatic castration-resistant prostate cancer? Future oncology (London, England) (2023)
Bulent Cetin, Chiara A Wabl, Ozge Gumusay
Advancing immunotherapy in gastroesophageal cancer through rational combinations and biomarkers. Immunotherapy (2023)
Bulent Cetin, Chiara A Wabl, Ozge Gumusay
Should one use the combination of abiraterone and poly(ADP-ribose) polymerase inhibitors as first-line therapy for all patients with metastatic castration-resistant prostate cancer? Future oncology (London, England) 18 (39) (2023)
Bulent Cetin, Chiara A Wabl, Ozge Gumusay
Should one use the combination of abiraterone and poly(ADP-ribose) polymerase inhibitors as first-line therapy for all patients with metastatic castration-resistant prostate cancer? Future oncology (London, England) 18 (39) (2023)
Bulent Cetin, Chiara A Wabl, Ozge Gumusay
Should one use the combination of abiraterone and poly(ADP-ribose) polymerase inhibitors as first-line therapy for all patients with metastatic castration-resistant prostate cancer? Future oncology (London, England) 18 (39) (2023)
Bulent Cetin, Chiara A Wabl, Ozge Gumusay
CDK4/6 inhibitors: mechanisms of resistance and potential biomarkers of responsiveness in breast cancer. Future oncology (London, England) 18 (9) (2022)